Security
APOPW · Quoin Pharmaceuticals Ltd.
APOPWNASDAQWarrantHistorical · closed Aug 4, 2021CIK 1671502Updated Sep 24, 2026
Name history
Quoin Pharmaceuticals, Ltd. · through Sep 1, 2026Cellect Biotechnology Ltd. · through Oct 15, 2021Cellect Biomed Ltd. · through Jul 7, 2016
APOPW price & chart
Historical security
This listing closed Aug 4, 2021. Live provider charts are shown only for current listings.
About the company
Quoin Pharmaceuticals Ltd. Is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
In the news
No coverage from other publishers is available.
Recent filings
PRE 14A filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-3 filing
D filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
4 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure · Other Events
Items 1.01, 3.02, 7.01, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders · Other Events
Items 5.02, 5.07, 8.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 20,390,569Source | 15,709,338Source | 12,169,229Source | 14,458,063Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 383,334Source | 483,334Source | 583,334Source | 704,561Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,818,096Source | 3,623,343Source | 2,401,198Source | 2,860,628Source |
| Assets, CurrentUSD | 20,007,235Source | 14,926,004Source | 11,285,895Source | 13,370,112Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,261,974Source | 869,126Source | 591,034Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,270,663Source | 6,504,665Source | 6,505,213Source | 7,051,289Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Additional Paid in CapitalUSD | 84,090,966Source | 64,370,465Source | 51,867,336Source | 47,855,521Source |
| Retained Earnings (Accumulated Deficit)USD | -70,970,447Source | -55,165,792Source | -46,203,320Source | -37,516,747Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -613Source | 55,200,000Source | 46,200,000Source | 37,500,000Source |
| Stockholders' Equity Attributable to ParentUSD | 13,119,906Source | 9,204,673Source | 5,664,016Source | 7,406,774Source |
| Liabilities and EquityUSD | 20,390,569Source | 15,709,338Source | 12,169,229Source | 14,458,063Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,546,930Source | 4,180,932Source | 3,581,480Source | 3,527,556Source |
| Accounts Payable, CurrentUSD | 1,262,222Source | 905,704Source | 526,523Source | 605,600Source |
| Other Liabilities, NoncurrentUSD | 1,723,733Source | 2,323,733Source | 2,923,733Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,538,457Source | 1,528,977Source | 1,308,706Source | 1,175,705Source |
| Short-term InvestmentsUSD | 14,927,165Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -15,804,655Source | -8,962,472Source | -8,686,573Source | -9,381,496Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,147,236Source | 1,258,890Source | 1,094,549Source | 764,007Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,540,994Source | -7,857,309Source | -7,864,429Source | -8,480,732Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,277,775Source | -1,888,282Source | 2,188,316Source | -10,149,121Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,014,135Source | 10,967,736Source | 5,216,683Source | 14,007,708Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 194,753Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,818,096Source | 3,623,343Source | 2,401,198Source | 2,860,628Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,150,000Source | 1,260,000Source | 1,090,000Source | 764,000Source |
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 103,706Source | 104,043Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 416,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | 0Source | 0Source | 1Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | 18,000Source | 18,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -15,804,655Source | -8,962,472Source | -8,686,573Source | -9,381,496Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,686,573Source | -9,446,762Source |
| Nonoperating Income (Expense)USD | 486,061Source | 565,993Source | 691,931Source | -123,792Source |
| Operating Costs and ExpensesUSD | 16,290,716Source | 9,528,465Source | 9,378,504Source | 9,257,704Source |
| Payments to Acquire InvestmentsUSD | 12,264,069Source | 17,254,282Source | 18,090,684Source | 9,899,121Source |
| Proceeds from Issuance of Common StockUSD | 18,614,135Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | 3,980Source | 7,502Source | -2,683Source | 1,307Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 251,590Source | 489,079Source | 93,779Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 6,487,909Source | 5,925,833Source | 6,070,517Source | 6,584,868Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -15,804,655Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -15,804,655Source | -8,962,472Source | -8,686,573Source | -9,381,496Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 103,706Source | 104,043Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -15,722,913Source | — | — | — |
| Interest Income, OtherUSD | — | — | — | 95,745Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,686,573Source | -9,446,762Source |
| Nonoperating Income (Expense)USD | 486,061Source | 565,993Source | 691,931Source | -123,792Source |
| Operating Costs and ExpensesUSD | 16,290,716Source | 9,528,465Source | 9,378,504Source | 9,257,704Source |
| Research and Development ExpenseUSD | 9,802,807Source | 3,602,632Source | 3,307,987Source | 2,672,836Source |
Filing attachments
tm2625948d1_ex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need Follows July 2026 FDA Clearance …
Read attachment ↗tm2625203d1_ex99-1.htm · 8-K · 2026-09-10
EX-99.1 2 tm2625203d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) ─────────────────────────────────…
Read attachment ↗tm2624258d1_ex4-1.htm · 8-K · 2026-08-28
EX-4.1 2 tm2624258d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE ORDINARY SHARES (“SHARES”) REPRESENTED BY THE AMERICAN DEPOSITARY SHARES (THE “ADSs”) ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY U.S. STATE OR OTHER U.S. JURISDICTION. this Warrant, THE ADSs and THE SHARES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN A TRANSACTION TH…
Read attachment ↗tm2624258d1_ex4-2.htm · 8-K · 2026-08-28
EX-4.2 3 tm2624258d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 THIS WARRANT AND THE ORDINARY SHARES (“SHARES”) REPRESENTED BY THE AMERICAN DEPOSITARY SHARES (THE “ADSs”) ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY U.S. STATE OR OTHER U.S. JURISDICTION. this Warrant, THE ADSs and THE SHARES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN A TRANSACTION TH…
Read attachment ↗tm2624258d1_ex99-1.htm · 8-K · 2026-08-28
EX-99.1 7 tm2624258d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million August 28, 2026 ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institution…
Read attachment ↗tm2624258d1_ex99-2.htm · 8-K · 2026-08-28
EX-99.2 8 tm2624258d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) W…
Read attachment ↗